TP53 Mutated MDS Patients Respond Equally to Hypomethylating Agents but Have Significantly Shorter Response Duration Compared to Patients with Wild Type TP53

被引：0
|
作者：
Takahashi, Koichi [1 ]
Kantarjian, Hagop M. [1 ]
Patel, Keyur [2 ]
Bueso-Ramos, Carlos E. [2 ]
Kadia, Tapan [1 ]
Jabbour, Elias [1 ]
DiNardo, Courtney [1 ]
Daver, Naval [1 ]
Pierce, Sherry [1 ]
Futreal, Andrew [3 ]
Garcia-Manero, Guillermo [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Is TP53 Mutated AML the Same Disease as TP53 Mutated MDS?
    Valk, Peter J. M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S3 - S5
  • [2] TP53 Mutated del(5q) Myelodysplastic Syndromes (MDS) Patients Have Survivals Comparable to Those with TP53 Wild-Type
    Chan, Onyee
    Al Ali, Najla
    Sallman, David
    Padron, Eric
    Lancet, Jeffrey
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S324 - S324
  • [3] Smoking and Its Prognostic Effect on Survival in Patients with TP53 Mutated MDS
    Reilly, Sean Patrick
    Bi, Xia
    French, Zachary
    Wilde, Lindsay
    Palmisiano, Neil
    BLOOD, 2022, 140 : 12339 - 12340
  • [4] Outcome of Myelodysplastic Syndrome Patients with TP53 Mutation Treated with Hypomethylating Agents
    Komrokji, Rami S.
    Sallman, David A.
    Al Ali, Najla
    Padron, Eric
    Sweet, Kendra
    Lancet, Jeffrey E.
    List, Alan F.
    BLOOD, 2017, 130
  • [5] Expression of wild-type and mutated TP53 in breast carcinomas
    Baumbusch, LO
    Myhre, S
    Langerod, A
    Bergamaschi, A
    Johnsen, H
    Geisler, S
    Lonning, PE
    Borresen-Dale, AL
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S53 - S53
  • [6] TP53 AND EZH2 MUTATIONS PREDICT POOR SURVIVAL IN PATIENTS TREATED WITH HYPOMETHYLATING AGENTS IN MDS
    Cedena, M. T.
    Rapado, I.
    Ayala, R. M.
    Onecha, E.
    Abaigar, M.
    Such, E.
    Ramos, F.
    Cervera, J. V.
    Hernandez-Rivas, J. M.
    Sanz, G.
    Martinez-Lopez, J.
    HAEMATOLOGICA, 2016, 101 : 68 - 68
  • [7] THERAPEUTIC USE OF IBRUTINIB IN PATIENTS WITH MUTATED LLC TP53
    Adrian, Segura D.
    Natalia, Espinosa L.
    Laura, Lacalle A.
    Marta, Villalba M.
    Gonzalo, Ferrer G.
    Gonzalo, Caballero N.
    Ana Cristina, Godoy M.
    Araceli, Rubio M.
    Pilar, Delgado B.
    HAEMATOLOGICA, 2016, 101 : 335 - 335
  • [8] Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
    A Langerød
    TI Andersen
    I Bukholm
    A-L Børresen Dale
    Breast Cancer Research, 2 (Suppl 1)
  • [9] Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients
    Ferrari, Anna
    Fonzi, Eugenio
    Fontana, Maria Chiara
    Di Rora, Andrea Ghelli Luserna
    Manfrini, Marco
    Padella, Antonella
    Baldazzi, Carmen
    Papayannidis, Cristina
    Marconi, Giovanni
    Paolini, Stefania
    Guadagnuolo, Viviana
    Perricone, Margherita
    Robustelli, Valentina
    Imbrogno, Enrica
    Franchini, Eugenia
    Venturi, Claudia
    Zuffa, Elisa
    Abbenante, Maria Chiara
    Simonetti, Giorgia
    Testoni, Nicoletta
    Ottaviani, Emanuela
    Giovanni, Martinelli
    CANCER RESEARCH, 2017, 77
  • [10] Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
    Sonkin, Dmitriy
    ELIFE, 2015, 4
12345